Polibar Plus
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle |
|---|---|
| Barium Sulfate Quelle : Sulfate de baryum | 105 % (p/v) |
Nicht arzneiliche Inhaltsstoffe
Chlorure de potassium, acide hydrochlorique, Acide citrique, solution de sorbitol à 70 %, Poly(sorbate) 80, Benzoate de sodium, citrate de sodium, Gomme arabique, Gomme de xanthane, Simethicone emulsion 30 %, Sodium carrageenan, Eau purifiée, Saveur de vanille, Sodium Saccharin, Sorbate de potassium
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | Non précisée | minimum : 60 mL ; maximum : 300 mL | Non précisée |
| Adultes | Non précisée | minimum : 500 mL ; maximum : 1 500 mL | Non précisée |
| Adultes | Non précisée | minimum : 340 mL ; maximum : 750 mL | Non précisée |
| Adultes | Non précisée | minimum : 1 000 mL ; maximum : 2 500 mL | Non précisée |
| Adultes | Non précisée | minimum : 150 mL ; maximum : 340 mL | Non précisée |
In Kanada zugelassene Verwendungen
For radiological study of the gastrointestinal tract. For radiological study of the gastrointestinal tract. For use as radiological contrast media for upper and lower gastrointestinal procedures by conventional x-ray or computed tomography. For radiological study of the gastrointestinal tract. (as stated on TPD previous approved label) For use as radiological contrast media for upper and lower gastrointestinal procedures by conventional x-ray. (as stated on TPD previous approved product information insert)
Originaltext auf Englisch.
N/A
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : For professional use only. Do not store after diluting. Do not use if seal is damaged. Store at controlled room temperature. See product information insert for complete details. Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium swallow studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. Administer initially small amounts such as a half-teaspoon of low-density barium and carefully observe swallowing under fluoroscopic control. If barium is aspirated into the larynx, further administration of barium should be immediately discontinued. If no aspiration is noted, additional barium may be given with continued fluoroscopic monitoring for aspiration. After any barium study of the G.I. tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the barium. To prevent barium impaction in the colon may also require the use of cathartics following completion of the examination. Saline cathartics are recommended on a routine basis and especially in patients with a history of constipation unless clinically contraindicated. Where enema tips are used, care must be taken during insertion into the patient, since forceful or too deep insertion may cause tearing or perforation of the rectum. When balloon retention tips are used, care should be taken to avoid over-inflation of the balloon, since overfilling or asymmetrical filling with displacement of the tip may occur. Such a displacement can lead to rectal perforation or barium granulomas. Inflation of the balloon should be done under fluoroscopic control by qualified profession personnel.
Originaltext auf Englisch.
Produktdaten
- Andere Namen
- EZDose
- Inhaber
- E-Z-EM Canada Inc.
- NPN oder DIN-HM
- 80027471
- Status
- Aktive Lizenz
- Lizenzdatum
- 27. September 2011
- Überarbeitungsdatum
- 25. Juni 2018
- Form
- Suspension
- Verabreichungsweg
- Orale, Rectale
- Art des Antrags
- Non traditionnelle
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80027471
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.